KALA BIO (NASDAQ:KALA) Rating Lowered to “Hold” at Lifesci Capital

KALA BIO (NASDAQ:KALA) was downgraded by equities research analysts at Lifesci Capital from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Other research analysts have also issued reports about the stock. HC Wainwright reiterated a “neutral” rating on shares of KALA BIO in a research note on Monday. Wall Street Zen lowered shares of KALA BIO from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Oppenheimer upped their target price on shares of KALA BIO from $15.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, September 11th. LADENBURG THALM/SH SH lowered shares of KALA BIO from a “buy” rating to a “neutral” rating in a research report on Monday. Finally, Mizuho started coverage on shares of KALA BIO in a research report on Monday, September 8th. They set an “outperform” rating and a $30.00 target price on the stock. One equities research analyst has rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, KALA BIO has a consensus rating of “Hold” and an average price target of $20.38.

KALA BIO Trading Down 25.4%

Shares of KALA BIO stock opened at $1.53 on Monday. KALA BIO has a 52-week low of $1.10 and a 52-week high of $20.60. The company has a quick ratio of 2.10, a current ratio of 2.10 and a debt-to-equity ratio of 3.19. The company’s 50-day simple moving average is $11.23 and its 200-day simple moving average is $6.84. The firm has a market cap of $10.74 million, a price-to-earnings ratio of -0.23 and a beta of -1.82.

KALA BIO (NASDAQ:KALA) last issued its quarterly earnings results on Friday, August 8th. The company reported ($1.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.82) by $0.11. As a group, equities research analysts anticipate that KALA BIO will post -10.84 earnings per share for the current year.

Institutional Trading of KALA BIO

Large investors have recently modified their holdings of the business. XTX Topco Ltd acquired a new stake in shares of KALA BIO in the second quarter valued at approximately $62,000. Readystate Asset Management LP acquired a new stake in shares of KALA BIO in the first quarter valued at approximately $243,000. Geode Capital Management LLC grew its position in shares of KALA BIO by 2.8% in the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company’s stock valued at $268,000 after purchasing an additional 1,534 shares during the last quarter. AIGH Capital Management LLC grew its position in shares of KALA BIO by 61.9% in the first quarter. AIGH Capital Management LLC now owns 196,350 shares of the company’s stock valued at $1,125,000 after purchasing an additional 75,048 shares during the last quarter. Finally, Woodline Partners LP acquired a new stake in shares of KALA BIO in the first quarter valued at approximately $1,483,000. 24.61% of the stock is currently owned by institutional investors and hedge funds.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.